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Summary.-The in vivo biological activity of various fractions and components of
haematoporphyrin derivative (HpD) have been determined by measuring the depth
of necrosis of implanted tumours in mice exposed to light after the administration
of standard doses of porphyrins dissolved in alkali.
In this assay, haematoporphyrin, hydroxyethylvinyldeuteroporphyrin and proto-
porphyrin are inactive, but the mono- and di-acetates of haematoporphyrin (which
are major components of HpD) and acetoxyethylvinyldeuteroporphyrin are Active.
However, the situation appears to be more complex than this. The normal method
for preparing HpD for injection involves an alkali treatment which causes hydrolysis
and elimination of the acetoxy functions, and the only recognized products (haemato-
porphyrin, hydroxyethylvinyldeuteroporphyrin and protoporphyrin) are inactive
in the in vivo assay. It is concluded that the active component here is a porphyrin,
possibly a dimer or oligomer, which is retained on the column during the normal
separation by HPLC. This conclusion is supported by the observations that (i) the
crude material obtained from the spent column is active without further alkali
treatment, and (ii) activity develops over 30 min, when HpD or the mono- or di-
acetates of haematoporphyrin are treated with sodium bicarbonate in aqueous
DMSO.
The advantages of working with a pure substance (e.g. haematoporphyrin
diacetate) rather than a mixture (HpD) are stressed.
HAEMATOPORPHYRIN DERIVATIVE (HpD)
has promise as a photosensitizing agent
for the treatment of neoplasms accessible
to light. On injection in vivo, it causes
tumours exposed to intense light in the
visible range to undergo rapid necrosis.
The combination of HpD and light
treatment has been applied with some
success in the therapy of superficial
tumours in man and laboratory rodents
(Diamond et al., 1972; Kelly et al., 1975;
Dougherty et al. 1978) and, with the aid
of fibre optic light-conducting systems, in
treating deep tumours in domestic animals
(Dougherty et al., 1981).
HpD is prepared by treating commercial
haematoporphyrin dihydrochloride with
sulphuric acid in glacial acetic acid
(Lipson & Baldes, 1960; Lipson et al.,
1961). It is a complex mixture, and it is
clearly important to identify the com-
ponents responsible for its anti-tumour
effects in vivo and to use these in a pure
form. HpD has therefore been fractionated
by preparative high-pressure liquid
chromatography (Bonnett et al., 1978,
1980, 1981) and we now report the
activities of the various components, as
judged by an in vivo assay using a trans-
plantable mouse tumour.
MATERIALS AND METHODS
HpD and other porphyrins.-HpD was
prepared from haematoporphyrin dihydro-
chloride (Koch Light, Colnbrook). Full
details of the preparation and fractionation
using high-pressure liquid chromatography
(HPLC) are given in Bonnett et al. (1981)
which also records the preparation of authen-517. C. BERENBAUM. R. B3ONE'TT AND) l'. A. SCOURIDES
tic samples of the porplhvrini carboxvlic
acids used here. The isomeric lhaematopor-
phyrins have not been previously character-
ized: thev were prepared by fractionating
lhaematoporphyrin using preparative HPLC
(Scourides. unpublished).
Pre1paration, of porphyriti soluations.-
Because the various porphyrins differed
markedlv in their solubility in aqueous
media and in their rates of solution, the
fillowing procedure wi-as devised. This en-
ab)led most of them to be dissolved rapidly
and conveniently. The porphyrin was dis-
solved in dimethyl sulphoxide (DMSO, if
necessary with w-arming) to make a 40mg/ml
solution, and this was diluted to 10 vols
with 0 5"/ sodium bicarbonate in Dul-
becco's phosphate-buffered physiological sal-
ine (PBS, Oxoid). The pH of the final solu-
tion wNas 70-7-2. In most cases an apparently
stable solution Awas formed; the exceptions,
and the methods used to deal with them.
are noted below. For the studies reported
in Table 1. Expt 1, injections wA-ere made
0-25-3 h after making up the solution; for
Expt 2 and those in Table 11, a fixed time
of 3 h wkas used.
Mouse tumour.-The PC6 myeloma, ob-
tained originally from the Chester Beatty
Re.search Institute. was passaged fort-
nightly in BALB/c female mice, by s.c.
injection of 106 viable cells. Cell viability,
was assessed by ability to hydrolyse fluores-
cin diacetate and to exclude ethidium
blromide.
Testing for- biological activity. Tumours
growing s.c. in the flanks of BALB/c female
mice weighing 18-2,5 g wNere used 10-14
days after implantation. when the tumours
wNere 6-10 mm in diameter, 5-7 mm deep.
and free from evident necrosis. In general, 6
mice Awere used to test each fraction in each
experiment, though fewer wtere used for the
sm-aller fractions. The numbers of mice used
in each test are specified in the Tables.
Porphyrins of knowNn constitution wNere
administered at a standard dose of 6-2 x 10-5
mol'/kg. HpD, and fractions which were
mixtures or of unknown constitution wN-ere
assigned a mean mol. wNt of650 (i.e. 6 2 x 1(-5
rnol/kg-40 mg/kg).
Solutions wN-ere injected i.v. in a volume of
01 m]/10 g body wNt. One day later. the skin
over the tumour was carefullv shaved and
the mouse was anaesthetized with Avertin
(Winthrop Laboratories) and covered wvith a
metal sshield witlh a circular lhole exposing
the tumour. The tumour was then illuminated
for 10 min with white light from a 1-6 kAV
xenon arc (Carl Zeiss photocoagulator) witlh
the follow\ing filters: (a) 10 cm water (b)
2 cm 1 O copper sulphate (c) 3 mm lheat-
absorbing filter 4602 (Optical Instrument
Services) (d) Calflex BI/K1 lieat-reflecting
filter (Balzer's High Vacuum). Measure-
ments with a 14BT tlhermopile (Laser
Instrumentation) showed a delivered energy
of 114 mW /cm2 at the skin surface. Measure-
ments wTitlh a thermocouple (Ellab. Copen-
hagen) inserted s.c. slhowN-ed that the s.c.
temperature did not rise more than 3-4°C
during 10 min exposure to light.
A day after illumination mice were given
0.6% Evans blue in physiological saline
(0-1 ml/10 g i.v.) and killed 2 h later. Tumours
-\ere fixed in formol-saline and sliced verti-
cally to the skin surface. The depth of
necrosis wN-as measured with a stereoscopic
microscope fitted with a micrometer eye-
piece. Specimens wNere coded and examined
in random order -without knowrledge of the
treatment applied. There was generally a
clear demarcation between the blue vascu-
larized tissue and white necrotic tissue (Fig.
1) and measurement of the depth of necrosis
usually presented no great difficulty if
measurements were made over the centre of
the tumour, where the skin surface was at
right angles to thle light beam. About 600
tumours -were used in the w-ork summarized
lhere. Results from 22 of these were excluded
from analysis because of interference by
superficial ulceration or spontaneous necrosis
(deep in the tumour and distributed irregu-
larly writhout relation to the direction of
illumination). W1here necrosis due to illumina-
tion involved the whole tumour thickness
(which occurred in about 1 tumour in 9)
it was assigned a depth equal to the tumour
thickness.
RESULTS
Chrormatographic separation
The separation ofthe major components
of HpD on a preparative scale by HPLC
has been described (Bonnett et al., 1981)
and a typical separation is shown, with
the components and fractions identified,
in Fig. 2. Fig. 3 provides structural
formulae and names. Under the prepara-
tive conditions used. the individuals of
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FIG. 1. Tumours from a control mouse (top)
and 3 mice given HpD and exposed to
light, showing 1, 1-5 and 2 5 mm depth of
necrosis, respectively. x 4.
positionally isomeric pairs [haemato-
porphyrin monoacetate (2, 3), hydroxy-
ethylvinyldeuteroporphyrin (4, 5), and
acetoxyethylvinyldeuteroporphyrin (7, 8)]
were not separated, and protoporphyrin
(9, a minor component) was not obtained
as a single fraction. It is essential that
the separation and work-up procedure be
carried out without delay in order to
minimize solvolysis and elimination of
the reactive acetoxy functions.
Biological activity of HpD fractions dis-
solved in alkali
Two such separations were carried out
for the purpose of biological testing.
Certain minor fractions which were ob-
tained in insufficient quantity for indivi-
dual testing were combined (for a given
separation) as shown in Table I, where the
results for the 2 experiments are com-
pared. The 2 experiments (i.e. separation
plus a complete set of bioassays) were
done at an interval of 6 months with 2
different batches of HpD. During this
interval the focusing of the light source
was improved, so that, while the mean
depth of damage with a standard dose of
HpD (40 mg/kg) was 1-4 + 0-6 mm for the
first set of observations, it had increased
to 36 + 0-9 mm by the time the second
set was made. Results for tests on the
HpD fractions are therefore expressed in
Table I as fractions of the depth of
damage concurrently observed with the
standard dose of HpD.
No activity was found in the polar
components (which emerged from the
column first, and which were combined
with other minor fractions). Haemato-
porphyrin and hydroxyethylvinyldeutero-
porphyrin (isomers) were also inactive.
On the other hand haematoporphyrin
diacetate, haematoporphyrin monoacetate
(isomers) and acetoxyethylvinyldeutero-
porphyrin (isomers), and interfraction
cuts containing these compounds were
all active, and did not differ materially
in activity at the doses given.
Biological activity of known hydrolysis
products of HpD (Table 11)
HpD is commonly prepared for injection
by treating it with 0 1M NaOH for l h at
room temperature (Dougherty et al.,
1978). Under these conditions the simple
porphyrin acetates do not survive, but
haematoporphyrin (1), hydroxyethyl-
vinyldeuteroporphyrin (4 and 5), and
protoporphyrin (9) are the major recog-
nized constituents (Bonnett et al., 1980).
These compounds, prepared by standard
methods, were tested in a separate series
of experiments. Samples of haemato-
porphyrin (pure, and the commercial
dihydrochloride) dissolved readily in
DMSO-bicarbonate-PBS, but were found
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Fraction Number
FIG. 2.-Preparative separation of components of HpD by HPLC. The major components are identi-
fied by analytical HPLC comparisons and spectroscopic methods (Bonnett et al., 1981). Because
of variations in Amax with structure, peak areas do not represent relative molar amounts of the
various compounds. Detector set at 400 nm.
to be inactive in vitro. So, too, were the
individual diastereoisomers (la, lb) of
haematoporphyrin. The individual iso-
mers (4 and 5) of hydroxyethylvinyl-
deuteroporphyrin, and a sample of pro-
toporphyrin, dissolved readily in DMSO,
but precipitated on dilution with bicar-
bonate-PBS. Solutions in DMSO, and
suspensions in DMSO-bicarbonate-PBS
given i.p., were inactive. Protoporphyrin
was also partially solubilized in aqueous
media by mixing the solution in DMSO
with 500 bovine serum albumin in PBS
or with mouse serum. These preparations
could be given slowly i.v. but, again,
produced no detectable photosensitiza-
tion of tumours (Table II).
Effect of time on the biological activity of
porphyrin acetates in aqueous bicarbonate
In view of the effect of base on the
composition of HpD, the bioassay was
extended to HpD solutions in which
solvolysis and elimination reactions were
minimized. Three types of solution were
used as follows: (i) HpD in neat DMSO,
given in a volume of 0 01-0 02 ml/10 g
(ii) HpD in DMSO diluted in PBS (pH
7.3) or in 05%o sodium acetate in PBS
and (iii) HpD in DMSO diluted in the
usual way with bicarbonate-PBS but
injected within 1 min of dilution. All
these preparations showed biological acti-
vity (Table III) which was less than that
observed with the bicarbonate-saline pre-
paration administered in the normal way
(when it was injected -30 min after
dilution). Timed injections showed that
HpD developed biological activity in
aqueous DMSO-bicarbonate-PBS solu-
tion; activity came to a maximum in
30 min, and did not then change
appreciably over 3 days (Table III). It
was this observation that led to the adop-
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Me<
Me-
Formula
R=R2 =CH(OH)Me
Rl =CH(OH)Me; R2 =CH(OAc)Me
R' =CH(OAc)Me; R2=CH(OH)Me
Rl=CH=CH2; R2=CH(OH)Me
R1=CH(OH)Me; R2=CH-CH2
Rl =R2=CH(OAc)Me
R1=CH CH2; R2=CH(OAc)Me
Rl =CH(OAc)Me; R2 =CH-CH2
Rl=R2=CH CH2
Name
Haematoporphyrin
81-O-Acetylhaematoporphyrin isomeric haematoporphiyrin
31-O-Acetylhaematoporphyrin f monoacetates
8-(1-Hydroxyethyl)-3-vinyldeuteroporphyrin
3-(1-Hydroxyethyl)-8-vinyldeuteroporphyrin
O,O-Diacetylhaematoporphyrin(haematoporphyrini diacetate)
8-(1-Acetoxyethyl)-3-vinyldeuteroporphyrin
3-(1-Acetoxyethyl)-8-vinyldeuteroporphyrin
Protoporphyrin
FIG. 3. Structures and names of identified components of HpD.
TABLE II.-Biological tests of the recognized components of activated HpD
Porphyrin
Haematoporphyrin(l)
Haematoporphyrin (la)*
Haematoporphyrin (lb)*
8-(1-Hydroxyethyl)-3-vinyl-
deuteroporphyrin (4)
3-(1-Hydroxyethyl-8-vinyl-
deuteroporphyrin (5)
Protoporphyrin (9)
HpD
HpD, activated in bicarbon-
ate and freeze-dried
HpD, activated in bicarbon-
ate and freeze-dried
Solvent and route
DMSO/bicarbonate PBS i.v.
DMSO/bicarbonate PBS i.v.
DMSO/bicarbonate PBS i.v.
DMSO i.p.
DMSO i.p.
DMSO/bicarbonate PBS suspension i.p.
DMSO i.p.
DMSO/BSA i.v.
DMSO/serum i.v.
DMSO/bicarbonate PBS i.v.
DMSO i.p.
DMSO/serum i.v.
* la and lb are diastereoisomers of haematoporphyrin, la being more polar (i.e. eluting first from thle
reverse-phase column).
tion of a fixed time of 3 h between pre-
paration of solutions and injection in the
experiment in Table I, Expt 2, and
subsequently.
This result was also obtained with the
individual constitutent esters. Solutions
of haematoporphyrin monoacetate (2, 3)
and haematoporphyrin diacetate (6) in
aqueous bicarbonate-PBS showed no acti-
vity when injected within 1 min of
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
Depth of
necrosis in
mm+s.d.
0
0
0
0
0
0
0
0
0
{2-31 +1-07
2-75 + 0*84
2-79+ 1*91
2*65+ 10-5
(No. of mice)
(12)
(6)
(6)
(4)
(6)
(6)
(6)
(3)
(5)
(4)
(6)
(6)
(5)
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TABLE III.-Activity of HpD in various solvents and the development of activity in
bicarbonate
Solvent
DMSO
DMSO
DMSO
DMSO/0-5% acetate
DMSO/PBS
DMSO/0 5% bicarbonate PBS <1 min
5-10 min
30 min
2 h
24 li
72 h
Route
s.c.
i.p.
im.m
Lv. i.V.
i.v.
i.V.
i.V.
i.VN.
i.v.
Depth of necrosis
in mm + s.d.
1 00+ 0.50
079 + 0-71
0 54 + 0-78
0-85 + 0-34
1-20 + 0 45
1-21 + 0 33
1-71+ 0 75
2-81 + 0-96
2-63 + 1-50
:304 + 1-58
3 04 + 1-95
TABLE IV. Activation of haematoporphyrin mono- and di-acetates by bicarbonate
Porphyrin
Haematoporphyrin monoacetate (2, 3)
Haematoporphyrin diacetate (6)
HpD
Time in
DMSO-bicarbonate
<1 min
3 lh
<1 min
3 h
3 h
Depth of necrosis
in mm + s.d.
0
2-35 + 0-78
0
2-90 + 1-34
2-60 + 0-89
dilution, but showed marked activity
when the diluted solution was injected 3 h
later (Table IV). Experiments on bicar-
bonate-PBS solutions of HpD stored in
the refrigerator showed unimpaired acti-
vity over several months.
Thus these experiments indicated that
the biological activity of HpD and its
main constituents, haematoporphyrin
mono- and di-acetates, increased on ex-
posure to base. However, the recognized
constituents of alkali-treated HpD that
passed through a HPLC column were
inactive. The most likely explanation was
that the active constituents of alkali-
treated HpD were retained on the column.
The following experiment was therefore
performed.
Fractionation of alkali-treated HpD
HpD (463 mg) was stirred in 0dIM
NaOH (20 ml) at room temperature and
in subdued light for 3 h. The solution was
neutralized with 2M HC1 and then acidi-
fied with a few drops of glacial acetic
acid to induce precipitation. Saturated
aqueous NaCl (10 ml) was added, and
the mixture was cooled. The precipitate
was removed and washed (with water) at
the centrifuge, and dried in vacuo.
A portion of the product was chromato-
graphed on Lichroprep RP-18 (25-40 Km,
195 g, packed in methanol at 10 bar,
conditioned with 1600 ml of elutriant)
using the Jobin-Yvon Chromatospac 10.
The porphyrin mixture was applied in
tetrahydrofuran (2.5 ml) + methanol (1 ml)
+elutriant (3 ml), and eluted with
methanol-water (3:1) containing 3% gla-
cial acetic acid. The eluate was divided
into 3 main fractions, A, B and C, rich
in haematoporphyrin, hydroxyethylvinyl-
deuteroporphyrin, and tail components
respectively. No interfraction cuts were
taken. The crude porphyrins were ob-
tained by removing the organic solvent
under reduced pressure. (A, 58 mg;
B, 47 mg; and C, 37 mg.)
The spent column was then washed
with solvents of increasing polarity. Frac-
tion D was brought off with tetrahydro-
furan :water (95:1, 1000 ml) and tetra-
hydrofuran-DMSO (4:1, 500 ml). Re-
moval of solvent in vacuo gave fraction D
(43 mg).
Finally the column was washed with
30% oxalic acid in ethanol (400 ml). The
(No. of mice)
(6)
(6)
(6)
(5)
(5)
(6)
(6)
(6)
(6)
(6)
(6)
(No. of mice)
(5)
(5)
(4)
(5)
(5)
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eluate was diluted with ethyl acetate
(300 ml), saturated NaCi (180 ml) was
added, and the pH was adjusted to
- 4-5. After equilibration the organic
layer was removed, and the aqueous
layer was re-extracted with a second
portion of ethyl acetate. The organic
extracts were combined and washed with
saturated NaCl solution (100 ml), 500o
saturated NaCl solution (100 ml) and
distilled water (100 ml). The solvent was
removed under vacuum to give Fraction
E (7 mg).
As the HpD thus fractionated had
already been "activated" by alkali, it was
reasoned that any active constituent
should be effective in vivo if injected
without further exposure to alkali. Ac-
cordingly, the dried fractions were dis-
solved in DMSO and injected i.p. in
volumes of 0-01 ml/10 g body wt. Freeze-
dried unfractionated alkali-activated HpD
was used as a standard. The results are
shown in Fig. 4. Although the repro-
ducibility of the results leaves something
to be desired, especially with HpD
(possibly due in part to incomplete
solution of this material in DMkSO), it is
clear that Fraction D contains most of
4'
3
4. __ __ __ *~~~~~~~~*
D:EHiD
Contros A B C D E HPD
Fic.. 4. Depth of ineerosis of tumouirs ill
control mice and mice given Fractions
A-E or unfractionated alkali-treated HpD.
Fractions A, B and C eltite(l with methanol-
water (3:1) with 3% acetic acid. Fraction
1) eluted with tetrally(lrofuran-water
(95: 1) and tetralhydrofuran-DMSO (4: 1).
Fraction E eluted with 3°, oxalic aeid in
ethanol. All materials gix-en in DMSO withi-
out further treatment. Each point repre-
sents I mouse.
the fractionated activity. There is also
some activity in Fraction A.
DISCUSSION
The effectiveness of a porphyrin in
photosensitizing different tissues depends
on two main factors. The first is the
degree of preferential localization of the
porphyrin, which in turn is related to the
solubility, partition, and transport char-
acteristics of the porphyrin and the
biochemical and biophysical properties of
the tissue. The second factor concerns
the photophysical parameters of the
porphyrin, particularly the quantumyield,
lifetimes and energies ofthe excited singlet
and triplet states. Present indications are
that, for samples of the pure porphyrins
identified in HpD, the photophysical
parameters are rather similar (Truscott,
personal communication) hence we think
that the properties which determine the
first factor are the crucial ones.
Clearly, the current practice of using a
complex mixture like HpD for photo-
therapy greatly complicates the problems
ofdeveloping this treatment and ofapply-
ing it to tumours at different sites. This
was our main motive for fractionating
HpD. Furthermore, the knowledge of
which porphyrins are active and which
inactivate in vivo is a prerequisite for
understanding how tumour damage is
caused, and for searching for more
effective porphyrin photosensitizers.
The nature of the test used to compare
porphyrins requires consideration. It is
important to recognize that porphyrins
may be effective photosensitizers in vitro
without necessarily being effective in
vivo. For example, haematoporphyrin
photosensitizes cells of human tumour
lines in vitro (Kessel, 1977; Christensen
et al., 1979; Moan et al., 1979; Sery, 1979;
Christensen, 1981) and protoporphyrin
sensitizes cultured human and mouse
tumour cells and chronic lymphocytic
leukaemia lymphocytes in vitro (Malik
and Djaldetti, 1980a, b) but both were
quite ineffective in our system. While
E
E
0
U
._
z
0
s
5) a
O
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solubility problems made it difficult to
examine protoporphyrin, and could partly
have accounted for its inactivity in vivo,
there were no such problems with haema-
toporphyrin. Activity in vivo depends not
only on photosensitizing phenomena, but
also on the ability of the sensitizer to
reach and accumulate in target cells.
Thus, while in vitro experiments are
essential in analysing the modes of
of action of porphyrins, in vivo work is
needed to discover which of them are
potentially useful in treating tumours.
Initially, our in vivo tests involved
comparing the growth rates of treated
and untreated tumours. These are not
reported here because it became apparent
that the effect of treatment was greatly
dependent on tumour geometry. Light
intensity falls off more or less exponen-
tially with depth of tissue (Eichler et al.,
1977; Dougherty et al., 1978) so that the
damaged proportion of a tumour depends
very much on its diameter parallel to
the light beam. A treatment that destroys,
say, the superficial half of one tumour
might completely destroy another tum-
our of the same volume but half the
thickness. The growth curve of the first
tumour might show merely a delay of
one doubling time, whereas the second
tumour would show complete regression.
Measurements of growth curves are there-
fore likely to yield useful results only
with tumours which have been highly
selected for uniformity of size and shape.
In contrast,the direct measurement of
the depth of tumour necrosis suffers no
such limitations. In our view this provides
a satisfactory measure of the overall
effectiveness of the treatment, though it is
possible that an additional effect is
mediated by the impairment of repro-
ductive integrity of cells in the tumour
beyond the limit of obvious necrosis
(Moan et al., 1979; Christensen & Moan,
1979; Christensen, 1981).
The present experiments have gone
part of the way towards identifying the
active constituents of HpD. In the
in vivo biological assay, haematopor-
phyrin (1), the hydroxyethylvinyldeutero-
porphyrin isomers (4 and 5), and proto-
porphyrin (9) show no activity, whereas
the porphyrin acetates [haematoporphyrin
monoacetate (2, 3), haematoporphyrin
diacetate (6) and acetoxyethylvinyldeu-
teroporphyrin (7, 8)] are all active, and
have rather similar activities. Were this
the end ofthe matter, it would betempting
to relate the biological activity to the
expected alkylating action of the pseudo-
benzylic acetate functions.
However, HpD is activated by the
presence of base (bicarbonate, hydroxide),
and its 2 major constituents (the haemato-
porphyrin mono- and di-acetates) are
not active until they have been treated
by base (bicarbonate, Table IV). Yet the
products of the alkali activation of
HpD, identified by HPLC (1, 4, 5, 9) are
not active in the in vivo assay. Hence it
appears necessary to postulate an addi-
tional type of component which is not
separated by our normal HPLC technique.
Support for this view comes from the
experiment in which HpD was treated
with NaOH, and then fractionated by
HPLC.
Of fractions collected in the normal
way, only Fraction A had moderate
activity, evidently not due to its main
constituent, haematoporphyrin. However,
when the spent column was treated with
two solvents ofconsiderable eluting power,
to bring off, in 2 fractions, material
strongly retained by the column, one of
these (Fraction D, Fig. 3) was found, when
dissolved in DMSO and injected without
further base treatment, to have activity
similar to that of base-activated un-
fractionated HpD.
The chemical interpretation of this
remains to be determined. It seems likely
that a porphyrin component, presumably
a dimer or oligomer, of higher mol. wt
has been formed, and this is now being
studied further. Since the O-acetates are
precursors of the biologically active
materials, and these compounds appear to
be stable, it seems likely thatC-O orC- C
bonds have been formed between mole-
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0 0
Me
10 C-O bond formation: dialkyl ether, benzylic, but
sterically hindered.
N NH
Me
C C bond formationi: robust, but oxercrowded
HN A molecule.
NH
Fie. 5.-Postulated bond(ing in (timer aii(I oligomer formation.
cules. Some possibilities are shown in
Fig. 5. Finally it is noted that special
caution with regard to purity is required
in tests on porphyrins, especially with
haematoporphyrin and its relatives. For
example, Granelli et al. (1975) found that
commercial haematoporphyrin photosensi-
tized rat glioma cells in vitro, but reported
that only about 50% of the material used
was haematoporphyrin. Again, Henderson
et al. (1980) found that the fluorescence
induced in tumours by haematoporphyrin
they had prepared was due largely to
contamination with haematoporphyrin
monoacetate. As far as the use of HpD is
concerned, it would appear advisable to
use a pure component of HpD of known
activity instead of the variable mixture
at present in use. Haematoporphyrin
diacetate (6) would appear to be the
most suitable for this purpose.
We are grateful to the Medical Research Council
for support, and to Mr L. Carr, Mr W. A. Cope and
Mr P. Johnson for assistance.
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